Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-fluoro-galactose-1-phosphate | competitively inhibit recombinant enzyme | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P07902 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HEK-293 cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
galactose-1-phosphate uridyltransferase | - |
Homo sapiens |
GALT | - |
Homo sapiens |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.9 | - |
2-fluoro-galactose-1-phosphate | pH and temperature not specified in the publication | Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | genetic defects of human galactose-1-phosphate uridyltransferase (hGALT) and the partial loss of enzyme function result in an altered galactose metabolism with serious long-term developmental impairment of organs in classic galactosemia patients. GALT deficiency (classic galactosemia) leads to an accumulation of galactose-1-phosphate, is associated with a potentially lethal acute hepatotoxic syndrome, unless affected newborns are kept under a galactose-restricted diet. Endogenously synthesized galactose however, can exert chronic cell toxic effects and worsen the prospects of patient son longer terms. Most patients suffer from a cognitive impairment, from speech defects, motor function disturbances, and a hypergonadotropic hypogonadism in female patients. The metabolic induction of galactosemia-like phenotypes in healthy epithelial/neuronal cells can support studies on the molecular pathomechanisms in classic galactosemia, in particular under conditions of low galactose stress and residual GALT activity | Homo sapiens |
metabolism | enzyme in the Leloir pathway | Homo sapiens |